Lineage Cell Therapeutics (LCTX) Total Current Liabilities (2010 - 2026)

Lineage Cell Therapeutics has reported Total Current Liabilities for 17 years, with the latest figure at $8.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 37.75% year-over-year to $8.1 million; the trailing twelve-month figure through Mar 2026 stood at $8.1 million (down 37.75% YoY), and the FY2025 full-year result was $11.4 million, down 18.67% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $8.1 million, down from $11.4 million in the prior quarter.
• The five-year high for Total Current Liabilities was $25.1 million in Q2 2022, with the low at $8.1 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $16.0 million across 5 years, with a median of $15.9 million in 2023.
• The largest YoY upside for Total Current Liabilities was 271.44% in 2022 against a maximum downside of 59.71% in 2022.
• Lineage Cell Therapeutics' Total Current Liabilities stood at $19.0 million in 2022, then retreated by 5.38% to $18.0 million in 2023, then dropped by 22.18% to $14.0 million in 2024, then fell by 18.67% to $11.4 million in 2025, then dropped by 28.32% to $8.1 million in 2026.
• The last three Total Current Liabilities figures came in at $8.1 million (Q1 2026), $11.4 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.